Peter Cutri, DO
Neurology · Garfield Heights, OHNPI 1780647990
Payments from drug & device makers
Across 215 payments — averaging $19.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$770
- Sanofi$528
- AbbVie$281
- Biogen$260
- Genentech USA, Inc.$238
- Lilly USA, LLC$226
- plus $2K from 24 others
What the payments were for
- Speaking & faculty fees$431%
- Food & beverage$4,19099%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 39 | $770 |
| Sanofi | 24 | $528 |
| AbbVie(2 entities) | 15 | $281 |
| Biogen | 11 | $260 |
| Genentech USA, Inc. | 14 | $238 |
| Lilly USA, LLC | 10 | $226 |
| Johnson & Johnson | 14 | $213 |
| AstraZeneca | 10 | $188 |
| EMD Serono, Inc. | 9 | $165 |
| Amgen | 6 | $155 |
| Kyowa Kirin, Inc. | 7 | $144 |
| Bristol Myers Squibb | 8 | $132 |
| Pfizer | 6 | $107 |
| Eisai Inc. | 5 | $91 |
| SK Life Science, Inc. | 3 | $82 |
| Neurelis, Inc. | 4 | $77 |
| Grifols USA, LLC | 4 | $73 |
| Acorda Therapeutics, Inc | 4 | $66 |
| TG Therapeutics, Inc. | 4 | $65 |
| Argenx US, Inc. | 3 | $62 |
| Nobelpharma America, LLC | 1 | $52 |
| E.r. Squibb & Sons, L.L.C. | 2 | $47 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $39 |
| Greenwich Biosciences, Inc. | 2 | $34 |
| Teva Pharmaceuticals USA, Inc. | 2 | $32 |
| Jazz Pharmaceuticals Inc. | 2 | $28 |
| UCB, Inc. | 1 | $21 |
| Sunovion Pharmaceuticals Inc. | 1 | $21 |
| Neurocrine Biosciences, Inc. | 1 | $20 |
| Avion Pharmaceuticals | 1 | $18 |
How this compares
$4,233 in reported general payments places this provider in the 60th percentile of 702 neurology providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Gammagard LiquidImmun Glob G(Igg)/Gly/Iga Ov50 | 13 | $212,280 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 49 | $1,978 |
| Memantine Hcl | 17 | $1,018 |
| Primidone | 25 | $899 |
| Donepezil Hcl | 111 | $820 |
| Phenobarbital | 12 | $383 |
| Topiramate | 12 | $139 |
| ClopidogrelClopidogrel Bisulfate | 19 | $123 |
| Sumatriptan Succinate | 11 | $120 |
Paid to pharmacies, not to this prescriber.
Other neurology in Garfield Heights
- Joel VandersluisDayton$12.3M
- Jerry MendellColumbus$11.5M
- Lawrence GoldstickDayton$6.9M
- Douglas ScharreColumbus$6.8M
- Robert BermelCleveland$6.4M
- Aaron BosterColumbus$6.3M
- Ryan DrakeCanton$5.5M
- Aram ZabetiCincinnati$5.3M
- Mark StillmanIndependence$4.6M
- Deren HuangNewark$4.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.